Cerulean Pharma Inc, a clinical-stage company developing nanoparticle-drug conjugates (NDCs), announced top-line results from the company's phase 2, randomized, multi-center clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in the treatment of patients with advanced renal cell carcinoma (RCC).
The US Food & Drug Administration (FDA) has granted orphan drug status for Pulmatrix Inc's inhaled drug for treating pulmonary fungal infections in cystic fibrosis (CF) patients, named PUR1900.